Zealand Pharma announced positive topline results on Thursday from a Phase 1b 16-week multiple ascending dose clinical trial of its long-acting amylin analog petrelintide. The early-stage study showed that a high dose of the drug helped reduce weight by an average of 8.6% after 16 weekly doses. The investigational obesity drug activates a hormone that is not targeted by popular treatments like Wegovy and Zepbound.
Zealand Pharma reported early positive results of an investigational obesity drug that activates a hormone that’s not targeted by treatments Wegovy and Zepbound. https://t.co/Fvz5yxDmVo
Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6% after 16 weekly doses. https://t.co/0vAGTR8sKN https://t.co/0vAGTR8sKN
Zealand’s $ZEAL amylin-targeting drug shows early potential in obesity https://t.co/mZZiPSb5Ia via @elaineywchen
STATNEWS: Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates a hormone that’s not targeted by popular treatments Wegovy and Zepbound. $NVO $LLY https://t.co/UNicv9LPFx
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide https://t.co/GXknmYHVPm https://t.co/3UJCoZu0tX